Skip to content
Awesome – Lifestyle
Author:
Spyre Therapeutics, Inc.
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
April 13, 2026
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
March 4, 2026
←
Previous Page
1
2
3